← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 607개
AntibodystaleRuijin HospitalPhase 2

Zanubrutinib + Rituximab + MTX ± Selinexor (Zanubrutinib + Rituximab + MTX ± Selinexor)

Central Nervous System Lymphoma · Central Nervous System Lymphoma

#CentralNervousSystemLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleFirst Affiliated Hospital of We…Phase 2

Zanubrutinib+Rituximab+Lenalidomide (Zanubrutinib+Rituximab+Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, Fludarabine, cyclophosphamide and rituximab (Zanubrutinib, Fludarabine, cyclophosphamide and rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

ZR2 (Zanubrutinib, Lenalidomide and Rituximab, Zanubrutinib, Lenalidomide and Rituximab (ZR2))

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, bendamustine, rituximab (Zanubrutinib, bendamustine, rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystalePeking UniversityPhase 2

Zanubrutinib, high-dose methotrexate (HD-MTX, Zanubrutinib, high-dose methotrexate, Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab)

Secondary Central Nervous System Lymphoma · Secondary Central Nervous System Lymphom

#SecondaryCentralNervousSystemLym#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital w…Phase 2

Zebetuzumab (Zebetuzumab)

Marginal Zone Lymphoma(MZL) · Marginal Zone Lymphoma(MZL)

#MarginalZoneLymphomaMZL#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleOu Bai, MDPhase 2

Zuberitamab-CHOP+orelabrutinib (Zuberitamab-CHOP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 2

^111 In Ibritumomab Tiuxetan (^111 In Ibritumomab Tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0.8%임상시험 1상태 DISCONTINUED
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai General Hospital, Shan…Phase 1

anti-CD7 CAR-T cells (anti-CD7 CAR-T cells)

T Lymphoblastic Leukemia/Lymphoma; T-cell Acute Lymphoblastic Leukemia · T Lymphoblastic Leukemia/Lymphoma

#TLymphoblasticLeukemiaLymphoma#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleXiangyang No.1 People's HospitalPhase 2

autologous NK cell (autologous NK cell)

NK Cell; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 0.667%임상시험 1상태 RECRUITING
CGTBiologicstaleMarino Biotechnology Co., Ltd.Phase 1

autologous anti-CD19 CAR T cells (autologous anti-CD19 CAR T cells)

B-cell Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleJoshua Sasine, MD, PhDPhase 1

autologous hematopoietic stem cells added to planned CAR T (autologous hematopoietic stem cells added to planned CAR T)

Hematologic Malignancy; Large B-cell Lymphoma · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleSeoul National University Hospi…Phase 2

bendamustine plus rituximab (bendamustine plus rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.8%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 93.8%임상시험 1상태 DISCONTINUED
AntibodystaleSingapore General HospitalPhase 1

bortezomib, rituximab, ifosphamide, etoposide, carboplatin (bortezomib, rituximab, ifosphamide, etoposide, carboplatin)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleYuLiPhase 2

dual target CAR-T cell therapy (dual target CAR-T cell therapy)

Lymphoma, B-Cell; Relapse/Recurrence · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE

29 / 31 페이지

← 이전다음 →